Y-MABS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.6 USD | -2.11% |
|
-5.54% | +70.09% |
| 05-08 | Transcript : Y-mAbs Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
| 05-07 | Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q1 Revenue $19.9M, vs. Street Est of $22.2M | MT |
Presenter SpeechTessa Romero (Analysts)Welcome, everyone to the 40th Annual JPMorgan Healthcar...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
11.6
USD
Average target price
21.33
USD
Spread / Average Target
+83.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +70.09% | 509M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- YMAB Stock
- News Y-mAbs Therapeutics, Inc.
- Transcript : Y-mAbs Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-11-2022 09
